Skip to content

Released Mar 10, 2016, after the close

10-K filed Mar 10, 2016, 70 days after period end · 0001390478-16-000088

Q4 2015 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$19.68MderivedN/M vs Q4 2014N/M vs Q1 2015
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$7,590,000N/M
Operating Cash Flowderived-$15,284,000N/M
Free Cash Flowderived-$15,356,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2015derived from reported figuresQ4 2014derived from reported figuresQ4 2013Q4 2012
Revenue—$3.20M$1.44M$1.44M
Net Income-$19.68M-$7.96M-$5.52M-$19.68M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR